We review long term results from the PHOTON Study with Eric Schneider, MD, Tennessee Retina, Nashville, TM.
We review the latest results from the Regenexbio sub retinal gene therapy program with Robert Avery MD, California Retina Consultants, Santa Barbara, CA
We discuss whether pegcetacoplan therapy of geography atrophy affects the progression of dry AMD with Paul Hahn MD PhD of PH Retina, Nanuet, New York.
We discuss the observation that resolution of retinal fluid at one month in eyes with nAMD treated with aflibercept 8mg may herald longer duration treatment intervals at week 96 with Michael Stewart,, MD, Knights Templar Professor of Ophthalmology, Mayo Clinic, Jacksonville, Florida.
We discuss the current state of the Good Days charitable foundation with Dr. Michael Lai, MD. PhD, Retina Group of Washington, Assistant Clinical Professor, Georgetown University School of Medicine
We discuss the long term results of the Oaks, Derby, and GALE studies looking at the benefit of early treatment of geographic atrophy in AMD with Dr. Roger Goldberg of Walnut Creek, California.
We discuss management of eyes with both geographic atrophy and neovascular AMD with Dr. Ted Leng of the Byers Eye Institute, Stanford University School of Medicine
We review the 6 month results of the Davio 2 trial of the Durayvu TKI delivery system for maintenance therapy of neovascular AMD with Dr. Carl Regillo of Wills Eye Hospital.
We discuss the latest promising results from the GALE extension study of pegcetacoplan with Dr. Ashkan Abbey of Texas Retina Associates
We discuss the promising phase I results of the Helios trial studying AXPAXLI TKI inhibitor implant for diabetic retinopathy with Dr. Dilsher Dhoot of California Retina Consultants.
We discuss the use of non steroidal inflammatory agents in the management of central serous chorioretinopathy with Dr. Michael Singer of San Antonio, Texas
We discuss remarkable preliminary results from the the use of intravitreal EYE-103, a novel Wnt pathway agonist in the treatment of DME and neovascular AMD with Dr. Charles Wykoff of Houston Texas.
We discuss the first interim results of a novel intravitreal gene therapy agent, 4D-150, with Dr. Arshad Khanani of Sierra Eye Associates and the University of Nevada Reno School of Medicine.
We discuss the use of a novel bispecific anti-VEGF Anti IL-6 Antibody Biopolymar Conjugate for the treatment of DME with Dr. Mark R. Barakat of Phoenix, AZ.
We discuss the occurrence of retinal vasculitis following pegcetcoplan therapy of geographic atrophy with Dr. Andrew Witkin of the New England Eye Center, Tufts University School of Medicine
We discuss the treatment results of high dose aflibercept in the eyes in the most severe quartile of diabetic macular edema with Dr. Roger Goldberg of Walnut Creek, California.
We discuss the use of an IL-6 inhibitor in the treatment of uveitis macular edema with Dr. Sumit Sharma of the Cole Eye Institute, Cleveland Clinic.
We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.
We discuss the unique results of the Annexon geographic atrophy Phase I clinical trial with Dr. Roger Goldberg of Bay Area Retina Associates, Walnut Creek, California
We review the latest diagnostic and therapeutic approaches for retinoblastoma with Dr. Jesse Berry, Associate Professor of Ophthalmology, Children's Hospital Los Angeles.